Biocon reports mixed Q2 results as Syngene weakness hits PAT
In short
Biocon said its generics revenue rose 10% to ₹774 crore and its biosimilars revenue rose 3% to ₹2,809 crore. The headline says profit after tax fell 51% because of weakness at Syngene.
This matters because sales in two key units grew, but profit still dropped sharply. The report does not give the full PAT number or explain the Syngene weakness.
What the reporting says
Biocon reported mixed second-quarter results, with its generics segment revenue rising 10% to ₹774 crore and biosimilars revenue up 3% to ₹2,809 crore, while the headline said PAT fell 51% as Syngene weakness weighed on earnings. The source snippet does not give the PAT figure or detail the Syngene issue, but it indicates pressure on overall profit despite segment growth. The immediate takeaway is weaker earnings quality.
Why it matters
Biocon’s second-quarter update showed higher revenue in its generics and biosimilars businesses, but the headline says profit after tax fell 51% because of weakness at Syngene. The figures suggest operating growth in some segments alongside profit pressure elsewhere. The source snippet does not give the full PAT number or explain the Syngene weakness, so the exact cause and scope of the earnings decline remain unclear.